Skye Bioscience participates in panel at Evercore obesity event

Members of Skye‘s management team; Punit Dhillon, Puneet Arora, MD, FACE, and Chris Twitty, PhD participated in a non-incretin therapeutics panel at Evercore’s concurrent investor-focused obesity event. Hosted by Evercore’s equity research analysts, Liisa Bayko and Umer Raffat, the panel featured notable obesity physicians Helena Rodbard, MD, FACP, MACE, and Sean Wharton, MD, PharmD. The panel reviewed the clinical and preclinical experience with the CB1 pathway and nimacimab’s peripheral CB1 blockade as well as the broader non-incretin toolkit supporting obesity care beyond the limits of the GLP-1 era. Title: Mechanistic Insights into Weight Loss and Metabolic Regulation of Obese Mice Treated with Nimacimab, a Peripherally-restricted CB1 Inhibitor: In this ADA symposium, Chris Twitty, PhD, CSO, reviewed the distinguishing characteristics of nimacimab, reiterated meaningful weight loss data from a pre-clinical diet-induced obesity model that underscores nimacimab’s potential as a standalone obesity treatment and as a combination therapy, and introduced new biomarker data showing important reductions in obesity-induced inflammation and liver steatosis. Title: Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity Mouse Model as Demonstrated by Weight Loss, Restored Hormonal Regulation, and Reduced Inflammatory Biomarkers: This poster highlighted nimacimab’s ability to achieve weight reduction and deliver comprehensive metabolic improvements including enhanced body composition, restoration of metabolic homeostasis, and improved hormonal profiles. These studies and presentations highlight that peripheral inhibition of CB1 using a monoclonal antibody that does not cross the blood-brain barrier is effective, and has differentiating yet complementary mechanisms that make it an ideal combination with incretin-based drugs.